Molecular Diagnostics Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cancer Biomark. 2010;8(4-5):293-307. doi: 10.3233/CBM-2011-0215.
Here we demonstrate the utility of high-density antibody microarrays for ovarian cancer biomarker discovery. This report describes the technology and how it can be optimized for hypothesis-generating and testing experiments. Our previous results validated the high density antibody array technology platform, the current work expands on it utilizing a second generation array that we tested with a larger set of ovarian case and control serum samples. We then describe our strategies and methods for result validation, including Western immunoblots to confirm antibody specificity. By comparing and combining the current results with our previous study, we solidified the case that the markers found could be used for ovarian cancer diagnosis using this technology. These results set the stage for further validation of these potential biomarkers and the use of this technology in future biomarker discovery studies.
在这里,我们展示了高密度抗体微阵列在卵巢癌生物标志物发现中的应用。本报告描述了该技术以及如何对其进行优化,以进行假设生成和测试实验。我们之前的结果验证了高密度抗体阵列技术平台,目前的工作利用我们用更大的卵巢病例和对照血清样本测试的第二代阵列对其进行了扩展。然后,我们描述了我们用于结果验证的策略和方法,包括 Western 免疫印迹以确认抗体特异性。通过比较和结合当前的结果与我们之前的研究,我们证实了使用该技术可以使用发现的标志物进行卵巢癌诊断。这些结果为进一步验证这些潜在的生物标志物以及在未来的生物标志物发现研究中使用该技术奠定了基础。